Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jens-Ulrich Stegmann

Showing results (1-10 of 20) with videos related to

Pageof 2
Sort By:
Trends in Pharmacological Sciences|October 12, 2021
Safety of medicines and vaccines - building next generation capabilityAndrew Bate, Jens-Ulrich Stegmann
Journal of Pain Research|January 4, 2011
Tapentadol immediate release: a new treatment option for acute pain managementMarc Afilalo, Jens-Ulrich Stegmann, David Upmalis
Vaccine|September 3, 2017
Results on exposure during pregnancy from a pregnancy registry for AS04-HPV-16/18 vaccineMarta López-Fauqued, Julia Zima, Maria-Genalin Angelo, et al.
Clinical Therapeutics|March 24, 2009
Efficacy and tolerability of tapentadol immediate release and oxycodone HCl immediate release in patients awaiting primary joint replacement surgery for end-stage joint disease: a 10-day, phase III, randomized, double-blind, active- and placebo-controlled studyCraig Hartrick, Ilse Van Hove, Jens-Ulrich Stegmann, et al.
Current Medical Research and Opinion|October 15, 2008
The efficacy and tolerability of multiple-dose tapentadol immediate release for the relief of acute pain following orthopedic (bunionectomy) surgery Jens-Ulrich Stegmann, Horst Weber, Achim Steup, et al.
Advances in Pharmacological and Pharmaceutical Sciences|February 1, 2024
A Model for Monitoring Spontaneously Reported Medication Errors Using the Adjuvanted Recombinant Zoster Vaccine as an ExampleChristophe Dessart, Fernanda Tavares-Da-Silva, Lionel Van Holle, et al.
Drug Safety|October 8, 2021
An Analysis of Spontaneously Reported Data of Vesicular and Bullous Cutaneous Eruptions Occurring Following Vaccination with the Adjuvanted Recombinant Zoster VaccinePaola Pirrotta, Fernanda Tavares-Da-Silva, Maribel Co, et al.
Current Medical Research and Opinion|May 19, 2009
A randomized, double-blind, placebo-controlled phase 3 study of the relative efficacy and tolerability of tapentadol IR and oxycodone IR for acute painStephen Daniels, Ed Casson, Jens-Ulrich Stegmann, et al.
European Journal of Pharmacology|April 28, 2009
Antinociceptive effects of systemic lidocaine: involvement of the spinal glycinergic systemUta Muth-Selbach, Henning Hermanns, Jens Ulrich Stegmann, et al.
Drug Safety|August 31, 2020
Post-Marketing Safety Surveillance for the Adjuvanted Recombinant Zoster Vaccine: MethodologyFernanda Tavares-Da-Silva, Olivia Mahaux, Lionel Van Holle, et al.
Pageof 2

Showing results (1-10 of 20) with videos related to

Sort By:
Pageof 2
Trends in Pharmacological Sciences|October 12, 2021
Safety of medicines and vaccines - building next generation capabilityAndrew Bate, Jens-Ulrich Stegmann
Journal of Pain Research|January 4, 2011
Tapentadol immediate release: a new treatment option for acute pain managementMarc Afilalo, Jens-Ulrich Stegmann, David Upmalis
Vaccine|September 3, 2017
Results on exposure during pregnancy from a pregnancy registry for AS04-HPV-16/18 vaccineMarta López-Fauqued, Julia Zima, Maria-Genalin Angelo, et al.
Clinical Therapeutics|March 24, 2009
Efficacy and tolerability of tapentadol immediate release and oxycodone HCl immediate release in patients awaiting primary joint replacement surgery for end-stage joint disease: a 10-day, phase III, randomized, double-blind, active- and placebo-controlled studyCraig Hartrick, Ilse Van Hove, Jens-Ulrich Stegmann, et al.
Current Medical Research and Opinion|October 15, 2008
The efficacy and tolerability of multiple-dose tapentadol immediate release for the relief of acute pain following orthopedic (bunionectomy) surgery Jens-Ulrich Stegmann, Horst Weber, Achim Steup, et al.
Advances in Pharmacological and Pharmaceutical Sciences|February 1, 2024
A Model for Monitoring Spontaneously Reported Medication Errors Using the Adjuvanted Recombinant Zoster Vaccine as an ExampleChristophe Dessart, Fernanda Tavares-Da-Silva, Lionel Van Holle, et al.
Drug Safety|October 8, 2021
An Analysis of Spontaneously Reported Data of Vesicular and Bullous Cutaneous Eruptions Occurring Following Vaccination with the Adjuvanted Recombinant Zoster VaccinePaola Pirrotta, Fernanda Tavares-Da-Silva, Maribel Co, et al.
Current Medical Research and Opinion|May 19, 2009
A randomized, double-blind, placebo-controlled phase 3 study of the relative efficacy and tolerability of tapentadol IR and oxycodone IR for acute painStephen Daniels, Ed Casson, Jens-Ulrich Stegmann, et al.
European Journal of Pharmacology|April 28, 2009
Antinociceptive effects of systemic lidocaine: involvement of the spinal glycinergic systemUta Muth-Selbach, Henning Hermanns, Jens Ulrich Stegmann, et al.
Drug Safety|August 31, 2020
Post-Marketing Safety Surveillance for the Adjuvanted Recombinant Zoster Vaccine: MethodologyFernanda Tavares-Da-Silva, Olivia Mahaux, Lionel Van Holle, et al.
Pageof 2